NCT06952231 is a Phase 3 clinical trial of Sitagliptin + Metformin in Diabetes Mellitus, sponsored by University of Lahore.

Who is sponsoring NCT06952231?

NCT06952231 is sponsored by University of Lahore.

What drugs are being tested in NCT06952231?

Interventions in NCT06952231: Sitagliptin + Metformin, Empagliflozin + Metformin.

What condition does NCT06952231 study?

NCT06952231 studies Diabetes Mellitus.

Is NCT06952231 still recruiting?

NCT06952231 is currently completed. Last updated 30 April 2025.

Last reviewed 2025-04-30 · How we verify

NCT06952231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed Phase 3 Last updated 30 April 2025

What this trial tests

Phase 3 trial testing Sitagliptin + Metformin in Diabetes Mellitus in 50 participants. Completed in 5 January 2025.

Timeline

21 May 2024

Primary endpoint
10 December 2024

5 January 2025

Quick facts

Lead sponsor	University of Lahore
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	21 May 2024
Primary completion	10 December 2024
Estimated completion	5 January 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Sitagliptin + Metformin — full drug profile →
Empagliflozin + Metformin

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

University of Lahore

Who can join

18 and older, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the effects of Sitagliptin and Empagliflozin in combination with metformin on High sensitivity C reactive proteins (hs-CRP) levels and efficacy in T2DM patients. The main question aims to answer are the difference in effect of Sitagliptin with metformin and Empagliflozin with metformin on the levels of hs-CRP, HbA1C, Fasting blood glucose and BMI in patients with type 2 diabetes millitis. The sample size for the trial is 25 participants in each group based on 95% level of confidence and 80% power of the study. Fifty participants fulfilling the eligibility criteria will be randomly divided into two groups * Group A will be taking sitagliptin 50 mg along with metformin 1000mg BD for 12 weeks and group B will be taking Empagliflozin 12.5mg along with metformin 50mg for 12 weeks. * They will visit the hospital fortnightly for check up for 1st month and then monthly for tests * Participants will keep the record of their fasting blood glucose levels and any adverse effects during course of study. Primary outcomes measures: hs-CRP Secondary outcome measures: HbA1c, fasting blood glucose (FBG), body mass index (BMI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sitagliptin + Metformin

Trials testing the same drug.

NCT07172269 — Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes · NA · completed

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other University of Lahore trials

Trials by the same sponsor.

NCT07420244 — Task-oriented Training Versus Group Circuit Training in Children With Quadriplegic Cerebral Palsy · NA · not yet recruiting
NCT07446218 — Pharmacist-led Interventions in Psychiatric Patients · NA · not yet recruiting
NCT07359378 — Progressive Resistance Exercise Versus Functional Training in Elderly With Risk of Fall. · NA · not yet recruiting
NCT07244913 — Therapeutic Effects of Instrument-assisted Versus Sound-assisted Soft Tissue Mobilization in Chronic Non-specific Low Ba · NA · recruiting
NCT07436624 — Kabat Rehabilitation Versus Kinesiology Taping in Bell's Palsy · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06952231 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Lahore
Last refreshed: 30 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06952231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing